Acino established its footprint in Ukraine by the acquisition of manufacturing plant Pharma Start in October 2015 and significantly expanded its business in 2018 with the commercialisation of nine Merck products for the treatment of cardiovascular and endocrine diseases in the CIS and neighboring countries. The company since has achieved double-digit growth year-on-year and is one of the fastest-growing pharmaceutical companies in Ukraine.
In 2024 Aсino in Ukraine received the Certificate of Good Distribution Practice (GDP) for the first time – the company has confirmed the European standards for the distribution of medicines. This certificate is a proof that the quality management system, logistics, storage, sales processes, as well as qualified and dedicated personnel guarantee a high level of quality assurance of products at all stages of distribution leading to the final consumer.
Products across Rx, OTC and food supplements
with over 22% CNS market share in Ukraine
International pharma company in Ukraine
Best companies in Ukraine according to the 2023 publications ekonomika+ and dsnews.ua
Among pharmaceutical companies in Ukraine,
according to Forbes Ukraine and robota.ua TOP employer rankings for 2024
Acino’s business across the CIS region and neighbouring countries covers Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.
The headquarters of Acino’s business in the CIS region and neighbouring countries is located in Kyiv with its EU GMP-certified manufacturing plant equipped with a R&D Center allowing us to launch 2-3 new effective and safe products every year.
For more information please visit: acino.ua, acino.kz, acino.by.
The Acino production site, Pharma Start, in Ukraine has successfully completed an EU GMP audit conducted by the State Agency...
For the first time, Acino in Ukraine has received the Certificate of Good Distribution Practice (GDP). Following a rigorous inspection...
Acino has been recognised as the top employer among pharmaceutical companies in Ukraine. This ranking is the result of a...
The agreement focuses on the distribution of orphan drugs developed for patients with conditions such as rheumatoid arthritis, cryopyrin-associated periodic...
The war in Ukraine means that many Ukrainian people have been displaced and have no longer access to such essentials,...
At Acino, we express our unwavering support for our colleagues, patients and customers in Ukraine, many of whom continue to...
Acino commercializes a leading and patented portfolio of medicines, dietary supplements and medical products in the region covering the therapeutic areas of Cardiovascular, Gastroendocrinology, Endocrinology, Oncology, Central Nervous System (CNS), Women Health, Pediatry and Over-The-Counter products (OTC).
Our manufacturing site in Kyiv applies the highest Acino quality standards. The implemented quality management system adheres to international standards such as ISO 9001:2015, ISO 22000:2018, ISO 14001:2015, and ISO 45001:2018, ensuring its effective operation.
We believe in entering partnerships for the expansion of our product portfolio, the acquisition of unique drug delivery technologies, and for specific dossiers that meet our commercial plans. We provide contract manufacturing services, offer products through distribution deals, as well as through out- and in-licensing. We strive for long-lasting relationships with suppliers, distributors, and customers.
We use cookies to create statistics that help us to improve the quality of our website and your user experience. By clicking on “Accept All”, you consent to the processing of data by Acino and the transfer of data to third parties. You can also tailor your consent for specific data processing purposes. Once you have made your choice, click on “Confirm”. Find detailed information and modify your preferences at any time in our Privacy Notice.
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
We would like to set Google Analytics cookies to help us analyse the traffic on our website.